Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025Commercial launch in the PRC of generic nintedanib for the ...

Progressive pulmonary fibrosis is not a diagnosis so much as a disease behavior and a clinical phenotype, says Anna-Maria ...

Pirfenidone use in patients with idiopathic pulmonary fibrosis may be linked to a lower incidence of lung cancer. Learn more.

It’s been a little over 10 years since the antifibrotics pirfenidone [Esbriet] and nintedanib [Ofev] were approved by the FDA. I think providers have become more comfortable over time with the use of ...

For treating pulmonary fibrosis, presently the pharmacological arsenal involves only two drugs, pirfenidone and nintedanib, which work to slow down the disease progression but do not completely ...

Dysbiosis is the condition of having imbalances in the microbial communities either in or on the body. Dysbiosis is associated with many diseases, such as inflammatory bowel disease and chronic ...

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Pirfenidone (CAS 53179-13-8) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ...

Based on drug type, the pirfenidone segment accounted for the highest share in 2020, holding around three-fourths of the global idiopathic pulmonary fibrosis market, and is expected to continue its ...

Based on drug type, the pirfenidone segment accounted for the highest share in 2020, holding around three-fourths of the global idiopathic pulmonary fibrosis market, and is expected to continue ...

The two drugs cleared by the U.S. Food and Drug Administration (FDA) are the kinase inhibitor nintedanib and synthetic pyridone drug pirfenidone but neither can reverse or halt disease progression, ...

PDE has a strong anti-fibrosis effect but needs more in-depth research. (7) Pirfenidone has broad-spectrum anti-fibrosis effects and is the first drug to demonstrate some efficacy for IPF, which was ...